
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Cabergoline | Cabergoline | 2007-03-07 | |||
| Octreotide | Octreotide | 2023-12-05 | ||||
| Padagis | Bromocriptine | Bromocriptine | 2008-10-01 | |||
| Ingenus | Cabergoline | Cabergoline | 2018-08-01 | |||
| Mylan | Bromocriptine | Bromocriptine | 2005-04-04 | |||
| Cabergoline | Cabergoline | 2013-12-02 | ||||
| Octreotide | Octreotide | 2011-02-10 | ||||
| Sandoz | Bromocriptine | Bromocriptine | 1998-01-13 | |||
| Novartis | Octreotide | Sandostatin | 1988-10-21 | $1,265 M | Q2/22-Q2/25 | |
| Pfizer | Cabergoline | Dostinex | 1996-12-23 | |||
| Zydus Therapeutics | Bromocriptine | Bromocriptine | 2008-07-30 | |||
| Sun Pharmaceutical Industries | Octreotide | Octreotide | 2008-03-04 | |||
| Apotex | Cabergoline | Cabergoline | 2013-03-08 |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|